DuPont Decomposition

Why does PPLPHARMA earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

-4.0% = -3.7% × 0.49 × 2.20

Latest: FY2026

Profitability

Net Margin

-3.7%

5.8% →-3.7%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.49x

0.51x →0.49x

Revenue per ₹ of assets

Leverage

Equity Multiplier

2.20x

1.91x →2.20x

Assets funded by equity vs debt

Trend Analysis

ROE declined by 9.6 pp over 5 years. Driven by net margin declining (5.8% → -3.7%), leverage rising (1.91x → 2.20x).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr5.8%0.511.915.6%
FY20230Cr-0Cr-2.6%0.482.14-2.8%
FY20240Cr0Cr0.2%0.531.940.2%
FY20250Cr0Cr1.0%0.581.931.1%
FY20260Cr-0Cr-3.7%0.492.20-4.0%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for PPLPHARMA

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

PPLPHARMA DuPont Analysis — ROE -4.0% | YieldIQ